slides · global inventory
Present Solution
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 24,547
Current window 15,781-15,810
Pages 819
Rows per page 30
Slide function
15,781-15,810 of 24,547
37
The slide uses a series of diagrams to illustrate the biological engineering features of the cell line.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · Solution1 hit
40
Uses a four-column layout to categorize value propositions.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
41
PoS stands for Probability of Success. The slide uses a timeline framework to contrast traditional drug development with Absci's approach.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
42
Uses a dot-plot style bar chart to represent revenue over a 25-year period.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
09
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
10
The chart compares Cyno Half-Life vs Human Half-Life, showing YTE mAbs outperforming WT mAbs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
11
The slide uses a 'before-after' logic to justify the combination strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
12
Uses a Venn diagram to show target overlap and a bar chart to show clinical efficacy improvement.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Golden Circle1 hit
18
The slide uses a central antibody diagram to annotate specific technical improvements over 1st generation mAbs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
19
Includes structural biology visualization and dose-response curves for two different adhesion targets.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
20
The slide demonstrates bio-equivalence in binding affinity to a specific T-cell population.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
26
The slide uses a standard 2x2 grid for program summary and a simple timeline for catalysts.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
33
The slide uses a Y-shaped antibody diagram to annotate specific technical improvements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
35
The slide uses two charts: a dose-response curve (left) and a scatter plot (right) to demonstrate competitive advantage.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
36
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
37
The visual uses a mountain-climbing metaphor to represent indication expansion.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
39
The slide uses a biological process diagram to illustrate the mechanism of action for three drug candidates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
43
The slide uses a Y-shaped antibody illustration to represent the combination therapy approach.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
44
The slide uses a Venn diagram to illustrate target overlap and a tree diagram to show potential combination therapy paths.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
53
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
54
The slide uses a pentagon diagram to represent the five pillars of their antibody engineering platform.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
55
The diagram illustrates the mechanism of FcRn-mediated antibody recycling, contrasting physiological affinity with high affinity.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
56
Includes two distinct chart types: a scatter plot for half-life correlation and bar charts for ADA rates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
11
argenx SE | Results Presentation Deck | 15 slidesargenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Key Messages1 hit
24
Aston Martin Lagonda | Results Presentation Deck | 28 slidesAston Martin Lagonda | Results Presentation Deck | 28 slides · Aston Martin Lagonda
Conference presentation Investor relations 1 hit
13
The slide uses a three-column layout to categorize AI applications in the pharmaceutical value chain.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
26
Includes a process diagram for complimentary mechanisms of ATTR-CM treatment.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations 1 hit
29
The slide uses a three-column layout to categorize decarbonization efforts into specific scopes and programs.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
05
The slide uses a high-contrast blue box to highlight the core product value proposition.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
06
Highlights the repurposing of the active ingredient in Viagra for a new indication with no current FDA-approved treatments.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit